PL2834241T3 - Formy polimorficzne (s)-2-(1-(9h-puryn-6-yloamino)propylo)-5-fluoro-3-fenylochinazolin-4(3h)-onu - Google Patents

Formy polimorficzne (s)-2-(1-(9h-puryn-6-yloamino)propylo)-5-fluoro-3-fenylochinazolin-4(3h)-onu

Info

Publication number
PL2834241T3
PL2834241T3 PL13757230T PL13757230T PL2834241T3 PL 2834241 T3 PL2834241 T3 PL 2834241T3 PL 13757230 T PL13757230 T PL 13757230T PL 13757230 T PL13757230 T PL 13757230T PL 2834241 T3 PL2834241 T3 PL 2834241T3
Authority
PL
Poland
Prior art keywords
phenylquinazolin
purin
ylamino
fluoro
propyl
Prior art date
Application number
PL13757230T
Other languages
English (en)
Inventor
Ernest CARRA
Michael Gerber
Bing Shi
Keiko Sujino
Duong Tran
Fang Wang
Jerry B. Evarts
Original Assignee
Gilead Calistoga Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2834241(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Calistoga Llc filed Critical Gilead Calistoga Llc
Publication of PL2834241T3 publication Critical patent/PL2834241T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
PL13757230T 2012-03-05 2013-03-05 Formy polimorficzne (s)-2-(1-(9h-puryn-6-yloamino)propylo)-5-fluoro-3-fenylochinazolin-4(3h)-onu PL2834241T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261606870P 2012-03-05 2012-03-05
PCT/US2013/029157 WO2013134288A1 (en) 2012-03-05 2013-03-05 Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
EP13757230.1A EP2834241B1 (en) 2012-03-05 2013-03-05 Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one

Publications (1)

Publication Number Publication Date
PL2834241T3 true PL2834241T3 (pl) 2021-07-12

Family

ID=49117265

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13757230T PL2834241T3 (pl) 2012-03-05 2013-03-05 Formy polimorficzne (s)-2-(1-(9h-puryn-6-yloamino)propylo)-5-fluoro-3-fenylochinazolin-4(3h)-onu

Country Status (31)

Country Link
US (3) US8865730B2 (pl)
EP (1) EP2834241B1 (pl)
JP (2) JP2015509537A (pl)
KR (1) KR20140133590A (pl)
CN (2) CN106146506A (pl)
AP (1) AP2014007875A0 (pl)
AR (1) AR090253A1 (pl)
AU (1) AU2013203620B2 (pl)
BR (1) BR112014021935A2 (pl)
CA (1) CA2864305C (pl)
CL (1) CL2014002358A1 (pl)
CO (1) CO7071131A2 (pl)
CR (1) CR20140460A (pl)
EA (3) EA201690461A1 (pl)
EC (1) ECSP14020478A (pl)
ES (1) ES2848273T3 (pl)
IN (1) IN2014DN07105A (pl)
MA (1) MA37379A1 (pl)
MD (1) MD20140100A2 (pl)
MX (1) MX2014010656A (pl)
NZ (1) NZ629684A (pl)
PE (1) PE20141792A1 (pl)
PH (1) PH12014501920A1 (pl)
PL (1) PL2834241T3 (pl)
PT (1) PT2834241T (pl)
SG (1) SG11201405446PA (pl)
SI (1) SI2834241T1 (pl)
TW (1) TW201350486A (pl)
UY (1) UY34656A (pl)
WO (1) WO2013134288A1 (pl)
ZA (1) ZA201405870B (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
US9737521B2 (en) 2012-11-08 2017-08-22 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
WO2015014315A1 (zh) 2013-08-01 2015-02-05 杭州普晒医药科技有限公司 一种抑制剂的晶型及其制备方法和用途
US20160244452A1 (en) * 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015092810A2 (en) 2013-11-20 2015-06-25 Cadila Healthcare Limited Amorphous form of idelalisib
JP2017502021A (ja) 2013-12-20 2017-01-19 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤のためのプロセス方法
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
EP2979692A1 (en) 2014-07-30 2016-02-03 Sandoz Ag Dosage form comprising a pressure sensitive solid form of an active pharmaceutical ingredient
EP3031808B1 (en) 2014-12-09 2018-06-27 ratiopharm GmbH Salt of idelalisib
EP3048104A1 (en) 2015-01-20 2016-07-27 Sandoz AG Amorphous and crystalline forms of idelalisib and process for forming the same
WO2016097314A1 (en) * 2014-12-19 2016-06-23 Sandoz Ag Amorphous and crystalline forms of idelalisib and process for forming the same
WO2016147206A1 (en) 2015-03-13 2016-09-22 Mylan Laboratories Limited Process for the preparation of amorphous idelalisib and its premix
CN106146501A (zh) * 2015-03-26 2016-11-23 江苏豪森药业集团有限公司 一种无定型激酶抑制剂的制备方法
CN106146500A (zh) * 2015-03-26 2016-11-23 江苏豪森药业集团有限公司 5-氟-3-苯基-2-[(1s)-1-(9h-嘌呤-6-基氨基)丙基]-4(3h)-喹唑啉酮晶型及其制备方法
WO2016157136A1 (en) 2015-04-02 2016-10-06 Mylan Laboratories Ltd Crystalline forms of idelalisib
CN108033961A (zh) * 2015-04-15 2018-05-15 上海方楠生物科技有限公司 一种艾德力布的无定型物及其制备方法
CN106146503A (zh) * 2015-04-16 2016-11-23 上海医药工业研究院 一种Idelalisib的制备方法
CZ2015347A3 (cs) 2015-05-22 2016-11-30 Zentiva, K.S. Pevné formy 5-fluor-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]chinazolin-4-onu a jejich příprava
CN106279171A (zh) * 2015-06-09 2017-01-04 南京安源生物医药科技有限公司 一种Idelalisib的制备方法
CN107995911B (zh) 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
EP4585597A1 (en) 2015-07-02 2025-07-16 F. Hoffmann-La Roche AG Benzoxazepin oxazolidinone compounds and methods of use
WO2017009333A1 (en) * 2015-07-13 2017-01-19 Synthon B.V. Method for purifying idelalisib
AU2016311136B2 (en) 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
CZ2015575A3 (cs) * 2015-08-26 2017-03-08 Zentiva, K.S. Soli 5-fluoro-3-fenyl-2-[(1S)-1-(9H-purin-6-ylamino)propyl]quinazolin-4-onu a jejich příprava
CN106565716B (zh) * 2015-10-10 2021-06-15 上海创诺制药有限公司 一种Idelalisib晶型A及其制备方法
HU231016B1 (hu) * 2015-11-30 2019-11-28 Egis Gyógyszergyár Zrt. Idelalisib új polimorf és szolvát formája
WO2017175184A1 (en) * 2016-04-07 2017-10-12 Laurus Labs Limited Process for preparation of amorphous form of idelalisib
EP3272348A1 (en) 2016-07-21 2018-01-24 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising idelalisib
CN106632337B (zh) * 2016-10-18 2018-11-20 湖北生物医药产业技术研究院有限公司 艾代拉里斯的晶型、药物组合物、制备方法和用途
US10870650B2 (en) 2017-04-24 2020-12-22 Natco Pharma Limited Process for the preparation of amorphous idelalisib
CN107573345B (zh) * 2017-09-12 2020-01-10 浙江乐普药业股份有限公司 一种艾代拉利司及其中间体的制备方法
CN109575027A (zh) * 2017-09-29 2019-04-05 宁波爱诺医药科技有限公司 一种抗肿瘤药物艾德力布的一水合物及其制备方法
WO2019178596A1 (en) 2018-03-16 2019-09-19 Johnson Matthey Public Limited Company Pyridine or n,n-dimethyl acetamide solvated solid state forms of solvated idelalisib, their use and preparation
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
GB202109006D0 (en) * 2021-06-23 2021-08-04 Anglo American Minerio De Ferro Brasil S/A Method of and system for operating a grinding mill
CN116410195B (zh) * 2021-12-31 2025-07-18 同润生物医药(上海)有限公司 一种己二酸盐结晶及其制备方法

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1053063A (pl) 1963-05-18
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2027645A1 (de) 1970-06-05 1971-12-09 Byk Gulden Lomberg Chemische Fa bnk GmbH, 7750 Konstanz Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
NL7204972A (pl) 1971-04-21 1972-10-24
US3897432A (en) 1971-04-21 1975-07-29 Merck & Co Inc Substituted benzimidazole derivatives
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
DE2644265C2 (de) 1976-09-30 1983-02-10 Bayer Ag, 5090 Leverkusen Chinazoline
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4183931A (en) 1977-09-08 1980-01-15 Research Corporation 2-Ketoalkyl-4(3H)-quinazolinones
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
DE2812635A1 (de) 1978-03-22 1979-09-27 Bayer Ag Heterocyclische verbindungen
JPS55118917A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
JPS55118918A (en) 1979-03-06 1980-09-12 Mitsubishi Electric Corp Production of quinazolone ring-containing epoxy resin
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6017375B2 (ja) 1979-06-20 1985-05-02 三菱電機株式会社 ポリアミド樹脂の製造方法
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
USRE35862E (en) 1986-08-18 1998-07-28 Emisphere Technologies, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US6696250B1 (en) 1986-12-03 2004-02-24 Competitive Technologies, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
DE69209183T2 (de) 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
US5658780A (en) 1992-12-07 1997-08-19 Ribozyme Pharmaceuticals, Inc. Rel a targeted ribozymes
GB9301000D0 (en) 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
US5378725A (en) 1993-07-19 1995-01-03 The Arizona Board Of Regents Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
US5480906A (en) 1994-07-01 1996-01-02 Eli Lilly And Company Stereochemical Wortmannin derivatives
EP0771204A4 (en) 1994-08-12 1999-10-20 Pro Neuron Inc METHOD FOR TREATING SEPSIS OR FLAMMABLE DISEASES WITH OXYPURINE NUCLEOSIDES
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US6043062A (en) 1995-02-17 2000-03-28 The Regents Of The University Of California Constitutively active phosphatidylinositol 3-kinase and uses thereof
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5948664A (en) 1996-02-29 1999-09-07 The Regents Of The University Of California PI 3-kinase polypeptides
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6303615B1 (en) 1996-05-15 2001-10-16 Pfizer Inc 2,3 disubstituded-4(3H)-quinazolinones
GB9611460D0 (en) 1996-06-01 1996-08-07 Ludwig Inst Cancer Res Novel lipid kinase
US5858753A (en) 1996-11-25 1999-01-12 Icos Corporation Lipid kinase
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
HUP0301101A3 (en) 1996-12-31 2009-03-30 Reddy S Res Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
YU41299A (sh) 1997-02-28 2002-09-19 Pfizer Products Inc. Atropizomeri 3-aril-4(3h)-hinazolinona i njihova upotreba kao ampa-receptor antagonista
ATE303997T1 (de) 1997-06-09 2005-09-15 Pfizer Prod Inc Chinazolin-4-on ampa antagonisten
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
IL125950A0 (en) 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
WO1999034804A1 (en) 1998-01-08 1999-07-15 The University Of Virginia Patent Foundation A2a adenosine receptor agonists
WO1999008501A2 (en) 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6100090A (en) 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6046049A (en) 1999-07-19 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of PI3 kinase p110 delta expression
EP1686120A3 (en) 1999-10-27 2007-05-30 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CN1891699A (zh) 2000-01-24 2007-01-10 基纳西亚股份有限公司 用于治疗的吗啉代基取代的化合物
AU2972701A (en) 2000-02-07 2001-08-14 Bristol Myers Squibb Co 3-aminopyrazole inhibitors of cyclin dependent kinases
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1278748B1 (en) 2000-04-25 2011-03-23 ICOS Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
US7026330B2 (en) 2002-05-30 2006-04-11 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
US20040092561A1 (en) 2002-11-07 2004-05-13 Thomas Ruckle Azolidinone-vinyl fused -benzene derivatives
BR0312650A (pt) 2002-07-10 2005-05-03 Applied Research Systems Derivados de benzeno fundido azolidinona-vinila
GB0217777D0 (en) 2002-07-31 2002-09-11 Novartis Ag Organic compounds
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CA2400254A1 (en) 2002-09-19 2004-03-19 University Health Network Compositions and methods for treating heart disease
HRP20131159B1 (hr) 2002-09-30 2019-11-01 Bayer Ip Gmbh Taljeni azol-pirimidin derivati
MXPA05005585A (es) 2002-12-06 2005-07-27 Warner Lambert Co Benzoxazin-3-onas y derivados de las mismas como agentes terapeuticos.
JP2006512357A (ja) 2002-12-20 2006-04-13 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンゾキサジンおよびその誘導体
BRPI0409063A (pt) 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pró medicamentos de inibidor de pi-3 cinase
EP1644360A1 (en) 2003-06-05 2006-04-12 Warner-Lambert Company LLC 3-substituted indoles and derivatives thereof as therapeutic agents
EP1636212B1 (en) 2003-06-05 2007-06-27 Warner-Lambert Company LLC Cycloalkylsulfanyl substituted benzo¬b|thiophenes as therapeutic agents
JP2006526608A (ja) 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド
MXPA05012953A (es) 2003-06-05 2006-02-13 Warner Lambert Co Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
US20040259926A1 (en) 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
WO2004108713A1 (en) 2003-06-05 2004-12-16 Warner-Lambert Company Llc Cycloalkyl and heterocycloalkyl substituted benzothiophenes as therapeutic agents
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050239809A1 (en) 2004-01-08 2005-10-27 Watts Stephanie W Methods for treating and preventing hypertension and hypertension-related disorders
RS55546B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilonozitol 3-delta kinaze
CA2566436C (en) 2004-05-13 2011-05-10 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
WO2005120511A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
US20090131512A1 (en) 2007-10-31 2009-05-21 Dynavax Technologies Corp. Inhibition of type I in IFN production
ES2674719T3 (es) * 2008-11-13 2018-07-03 Gilead Calistoga Llc Terapias para neoplasias hematológicas
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
ES2634492T3 (es) 2008-12-24 2017-09-28 Prana Biotechnology Ltd Compuestos de quinazolinona
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
MX2011011036A (es) 2009-04-20 2012-01-20 Gilead Calistoga Llc Metodos de tratamiento para tumores solidos.
US20110230465A1 (en) 2009-09-18 2011-09-22 Boehringer Ingleheim International Gmbh Viral polymerase inhibitors
US20110306622A1 (en) * 2010-06-11 2011-12-15 Calitoga Pharmaceuticals, Inc. Methods of treating hematological disorders with quinazolinone compounds in selected subjects
US20130143902A1 (en) * 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
ES2848273T3 (es) 2012-03-05 2021-08-06 Gilead Calistoga Llc Formas polimórficas de (S)-2-(1-(9H-purin-6-ilamino)propilo)-5-fluoro-3-fenilquinazolina-4(3H)-ona
CA2934534A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one

Also Published As

Publication number Publication date
EA201491473A1 (ru) 2015-03-31
AU2013203620B2 (en) 2015-11-19
MX2014010656A (es) 2015-03-03
EA201690461A1 (ru) 2016-11-30
CL2014002358A1 (es) 2015-04-24
AR090253A1 (es) 2014-10-29
US9469643B2 (en) 2016-10-18
EP2834241A4 (en) 2015-11-11
IN2014DN07105A (pl) 2015-04-24
EA025407B1 (ru) 2016-12-30
PH12014501920A1 (en) 2014-11-24
US20130252976A1 (en) 2013-09-26
US20150080572A1 (en) 2015-03-19
JP2015509537A (ja) 2015-03-30
CA2864305A1 (en) 2013-09-12
CN104334560A (zh) 2015-02-04
ZA201405870B (en) 2015-11-25
JP2016104823A (ja) 2016-06-09
US10730879B2 (en) 2020-08-04
UY34656A (es) 2013-10-31
KR20140133590A (ko) 2014-11-19
MD20140100A2 (ro) 2015-01-31
US8865730B2 (en) 2014-10-21
PT2834241T (pt) 2021-02-05
ES2848273T3 (es) 2021-08-06
HK1206345A1 (en) 2016-01-08
AP2014007875A0 (en) 2014-08-31
NZ629684A (en) 2016-10-28
BR112014021935A2 (pt) 2019-09-24
CO7071131A2 (es) 2014-09-30
WO2013134288A9 (en) 2014-08-28
SG11201405446PA (en) 2014-10-30
CN106146506A (zh) 2016-11-23
WO2013134288A1 (en) 2013-09-12
PE20141792A1 (es) 2014-12-07
EP2834241B1 (en) 2020-11-18
US20160376274A1 (en) 2016-12-29
ECSP14020478A (es) 2015-12-31
SI2834241T1 (sl) 2021-06-30
TW201350486A (zh) 2013-12-16
CA2864305C (en) 2021-02-16
EA201691327A1 (ru) 2017-03-31
CR20140460A (es) 2014-11-24
EP2834241A1 (en) 2015-02-11
MA37379A1 (fr) 2016-11-30

Similar Documents

Publication Publication Date Title
AP2014007875A0 (en) Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
AU2013203620A1 (en) Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
HRP20200245T1 (hr) Postupci za pripravu (s)-1-(3-etoksi-4metoksifenil)-2-metansulfoniletilamina
IL237126A (en) Derivatives in cicadas
SG11201405750YA (en) Bicyclic pyrazinone derivatives
EP2818387A4 (en) STRUCTURE FOR THE FRONT PART OF A VEHICLE BODY
ZA201406082B (en) Use of ccr3-inhibitors
ZA201407529B (en) Process for the preparation of 2-deoxy-2-fluro-2-methyl-d-ribofuranosyl nucleoside compounds
EP2800747A4 (en) POLYMORPHY OF PERAMPANEL
GB201222832D0 (en) Manufacture of hollow parts
IL230598A0 (en) Polymorphic forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
EP2900243A4 (en) BICYCLIC OXA LACTAM KINASE HEMMER
IL237644A0 (en) Polymorphic forms of (s)-2-(1-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phenylquinazoline-4(3h)-one
PL2733011T3 (pl) Osprzęt sieci trakcyjnej
IL233446A0 (en) Polymorphic forms of paramphenel
AU2012903850A0 (en) Use of enantiomers of perhexiline